CytomX Therapeutics Inc Cash Flow Conversion Efficiency
CytomX Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, CytomX Therapeutics Inc (CTMX) has a cash flow conversion efficiency ratio of -0.060x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.07 Million) by net assets ($302.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of CytomX Therapeutics Inc (2013–2025)
Cash flow conversion efficiency of CytomX Therapeutics Inc from 2013 to 2025. This chart illustrates how CytomX Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of CytomX Therapeutics Inc for real-time trading data and today's change.
CytomX Therapeutics Inc Cash Flow Conversion Ratio Explained
CytomX Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
CytomX Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CytomX Therapeutics Inc ranked by their cash flow conversion efficiency. Also see market cap of CytomX Therapeutics Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tae Kwang Corporation
KQ:023160
|
0.012x |
|
Hangzhou Anysoft Information Technology Co Ltd
SHE:300571
|
0.066x |
|
Bichamp Cutting Technology Hunan Co Ltd
SHE:002843
|
-0.025x |
|
AQUILA PART PROD COM
RO:AQ
|
0.061x |
|
Duta Pertiwi Tbk
JK:DUTI
|
0.009x |
|
Clientele
JSE:CLI
|
-0.059x |
|
Unizyx Holding Corp
TW:3704
|
-0.141x |
|
SWS Hemodialysis Care Co. Ltd. A
SHG:688410
|
N/A |
Annual Cash Flow Conversion Efficiency for CytomX Therapeutics Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of CytomX Therapeutics Inc from 2013 to 2025. Review CTMX cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $99.01 Million | $-75.59 Million | -0.763x | -100.40% |
| 2024-12-31 | $-456.00K | $-86.23 Million | 189.103x | +15912.09% |
| 2023-12-31 | $-47.45 Million | $-56.03 Million | 1.181x | -8.59% |
| 2022-12-31 | $-85.75 Million | $-110.79 Million | 1.292x | +197.01% |
| 2021-12-31 | $89.38 Million | $-119.03 Million | -1.332x | -96.86% |
| 2020-12-31 | $-7.77 Million | $5.26 Million | -0.676x | +75.39% |
| 2019-12-31 | $51.11 Million | $-140.48 Million | -2.748x | -376.32% |
| 2018-12-31 | $130.88 Million | $-75.52 Million | -0.577x | -123.67% |
| 2017-12-31 | $69.90 Million | $170.37 Million | 2.438x | +9514.09% |
| 2016-12-31 | $78.48 Million | $-2.03 Million | -0.026x | +88.09% |
| 2015-12-31 | $126.07 Million | $-27.41 Million | -0.217x | +46.29% |
| 2014-12-31 | $-78.54 Million | $31.80 Million | -0.405x | -323.89% |
| 2013-12-31 | $-44.28 Million | $-8.01 Million | 0.181x | -- |
About CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell… Read more